127 related articles for article (PubMed ID: 37155942)
41. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
42. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
43. Genomic diversity of colorectal cancer: Changing landscape and emerging targets.
Ahn DH; Ciombor KK; Mikhail S; Bekaii-Saab T
World J Gastroenterol; 2016 Jul; 22(25):5668-77. PubMed ID: 27433082
[TBL] [Abstract][Full Text] [Related]
44. PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations.
Wu FH; Wei HZ; Deng HY; Xiao GH; Zhang YC
Neoplasma; 2023 Feb; 70(1):1-14. PubMed ID: 36129834
[TBL] [Abstract][Full Text] [Related]
45. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
46. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
47. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
48. The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients.
Peng J; Huang D; Poston G; Ma X; Wang R; Sheng W; Zhou X; Zhu X; Cai S
Oncotarget; 2017 Jul; 8(30):49076-49083. PubMed ID: 28416767
[TBL] [Abstract][Full Text] [Related]
49. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
50. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
51. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
52. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.
Nakano K; Yamamoto H; Fujiwara M; Koga Y; Tsuruta S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
Am J Surg Pathol; 2018 Feb; 42(2):172-182. PubMed ID: 28877066
[TBL] [Abstract][Full Text] [Related]
54. Molecular Profiling in Metastatic Colorectal Cancer.
Armstrong SA; Malley R; Weinberg BA
Oncology (Williston Park); 2020 Sep; 34(9):352-355. PubMed ID: 32965665
[TBL] [Abstract][Full Text] [Related]
55. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
56. The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.
Kim TW; Hwang SW; Kim KO; Cha JM; Joo YE; Cho YS
Oncology; 2023; 101(1):49-58. PubMed ID: 36191562
[TBL] [Abstract][Full Text] [Related]
57. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
58. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
59. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
60. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]